Marine bromophenol bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, represses angiogenesis in HUVEC cells and in zebrafish embryos via inhibiting the VEGF signal systems

Biomedicine and Pharmacotherapy

Volumn 75, Issue , 2015, Pages 58-66

  Qi, Xin ^a   Liu, Ge ^b   Qiu, Lin ^c   Lin, Xiukun ^d   Liu, Ming ^a  

^a Laboratory for Marine Science and Technology   (China)

^b INSTITUTE OF OCEANOLOGY   (China)

^c Chinese Academy of Sciences   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Antiangiogenesis; Bis(2,3 dibromo 4,5 dihydroxybenzyl) ether; VEGF; VEGFR; Zebrafish

Indexed keywords

ANGIOGENESIS INHIBITOR; BENZENE DERIVATIVE; CASPASE 9; EPIDERMAL GROWTH FACTOR RECEPTOR; ETHER DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROCASPASE 9; PROTEIN BAX; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; BIS(2,3-DIBROMO-4,5-DIHYDROXYBENZYL) ETHER; CATECHOL DERIVATIVE; VASCULOTROPIN A; VEGF PROTEIN, ZEBRAFISH; VEGFA PROTEIN, HUMAN; ZEBRAFISH PROTEIN;

ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER PREVENTION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL STRUCTURE; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAIN; UMBILICAL VEIN ENDOTHELIAL CELL; WESTERN BLOTTING; ZEBRA FISH; ANGIOGENESIS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CELL MOTION; DOSE RESPONSE; DRUG EFFECTS; EMBRYOLOGY; METABOLISM;

ANGIOGENESIS INHIBITORS; ANIMALS; CATECHOLS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHERS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PHYSIOLOGIC; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; S PHASE CELL CYCLE CHECKPOINTS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; ZEBRAFISH; ZEBRAFISH PROTEINS;

EID: 84944055038     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2015.08.033     Document Type: Article

References (34)

1. Ellis L.M., Liu W., Ahmad S.A., Fan F., Jung Y.D., Shaheen R.M., Reinmuth N. Overview of angiogenesis: biologic implications for antiangiogenic therapy. Semin. Oncol. 2001, 28:94-104.
2. Carmeliet P., Jain R.K. Angiogenesis in cancer and other diseases. Nature 2000, 407:249-257.
3. Chan L.S., Daruwalla J., Christophi C. Selective targeting of the tumour vasculature. ANZ J. Surg. 2008, 78:955-967.
4. Taraboletti G., Margosio B. Antiangiogenic and antivascular therapy for cancer. Curr. Opin. Pharmacol. 2001, 1:378-384.
5. Deplanque G., Harris A.L. Anti-angiogenic agents - clinical trial design and therapies in development. Eur. J. Cancer 2000, 36:1713-1724.
6. S. Loges, T. Schmidt, P. Carmeliet, Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates, 1 (2010).
7. García-Vilas J.A., Quesada A.R., edina M., Á M. 4-Methylumbelliferone inhibits angiogenesis in vitro and in vivo. J. Agric. Food Chem. 2013, 61:4063-4071.
8. Chao C.-Y., Lii C.-K., Ye S.-Y., Li C.-C., Lu C.-Y., Lin A.-H., Liu K.-L., Chen H.-W. Docosahexaenoic acid inhibits vascular endothelial growth factor (VEGF)-induced cell migration via the GPR120/PP2A/ERK1/2/eNOS signaling pathway in human umbilical vein endothelial cells. J. Agric. Food Chem. 2014, 62:4152-4158.
9. Lai Lin S., T.c Chen L., Kwok H.f., Lau C.B.-s., Cheung P.C.K. Antioxidant and antiangiogenic properties of phenolic extract from Pleurotus tuber-regium. J. Agric. Food Chem. 2014, 62:9488-9498.
10. Liu M Hansen P.E., Lin X. Bromophenols in marine algae and their bioactivities. Mar. Drugs 2011, 9:1273-1292.
11. Shoeib N.A., Bibby M.C., Blunden G., Linley P.A., Swaine D.J., Wheelhouse R.T., Wright C.W. In-vitro cytotoxic activities of the major bromophenols of the red alga Polysiphonia lanosa and some novel synthetic isomers. J. Nat. Prod. 2004, 67:1445-1449.
12. Han L.J., Xu N.J., Shi J.G., Yan X.J., Zeng C.K. Isolation and pharmacological activities of bromophenols from Rhodomela confervoides. Chin. J. Oceanol. Limnol. 2005, 23:226-229.
13. Ma M., Zhao J., Wang S., Li S., Yang Y., Shi J., Fan X., He L. Bromophenols coupled with methyl gamma-ureidobutyrate and bromophenol sulfates from the red alga Rhodomela confervoides. J. Nat. Prod. 2006, 69:206-210.
14. Shi D., Li J., Guo S., Su H., Fan X. The antitumor effect of bromophenol derivatives in vitro and Leathesia nana extract in vivo. Chin. J. Oceanol. Limnol. 2009, 27:277-282.
15. Popplewell W.L., Northcote P.T., Colensolide A. A new nitrogenous bromophenol from the New Zealand marine red alga Osmundaria colensoi. Tetrahedron Lett. 2009, 50:6814-6817.
16. Xu N., Fan X., Yan X., Li X., Niu R., Tseng C.K. Antibacterial bromophenols from the marine red alga Rhodomela confervoides. Phytochemistry 2003, 62:1221-1224.
17. Liu M., Wang G., Xiao L., Xu X., Liu X., Xu P., Lin X. Bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, a marine algae derived bromophenol, inhibits the growth of Botrytis cinerea and interacts with DNA molecules. Mar. Drugs 2014, 12:3838-3851.
18. Shi D., Xu F., He J., Li J., Fan X., Han L. Inhibition of bromophenols against PTP1B and anti-hyperglycemic effect of Rhodomela confervoides extract in diabetic rats. Chin. Sci. Bull. 2008, 53:2476-2479.
19. Kurihara H., Kawabata T.M.J., Takahashi K. Inhibitory potencies of bromophenols from Rhodomelaceae algae against α-glucosidase activity. Fish Sci. 1999, 65:300-303.
20. Kurihara H., Mitani T., Kawabata J., Takahashi K. Two new bromophenols from the red alga Odonthalia corymbifera. J. Nat. Prod. 1999, 62:882-884.
21. Kim K.Y., Nguyen T.H., Kurihara H., Kim S.M. Alpha-glucosidase inhibitory activity of bromophenol purified from the red alga Polyopes lancifolia. J. Food Sci. 2010, 75:H145-150.
22. Xu X., Song F., Wang S., Li S., Xiao F., Zhao J., Yang Y., Shang S., Yang L., Shi J. Dibenzyl bromophenols with diverse dimerization patterns from the brown alga Leathesia nana. J. Nat. Prod. 2004, 67:1661-1666.
23. Liu M Zhang W., Wei J Qiu L., Lin X. Marine bromophenol bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, induces mitochondrial apoptosis in K562 cells and inhibits topoisomerase I in vitro. Toxicol. Lett. 2012, 211:126-134.
24. Liu M., Zhang W., Wei J., Lin X. Synthesis and α-glucosidase inhibitory mechanisms of bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, a potential marine bromophenol α-glucosidase inhibitor. Mar. Drugs 2011, 9:1554-1565.
25. Liu G., Liu M., Wei J., Huang H., Zhang Y., Zhao J., Xiao L., Wu N., Zheng L., Lin X. CS5931, a novel polypeptide in Ciona savignyi, represses angiogenesis via inhibiting vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs). Mar. Drugs 2014, 12:1530-1544.
26. van C., ruijsen H., Giaccone G., Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int. J. Cancer 2005, 117:883-888.
27. Katoh M., Nakagama H. FGF receptors: cancer biology and therapeutics. Med. Res. Rev. 2014, 34:280-300.
28. Claesson-Welsh L., Welsh M. VEGFA and tumour angiogenesis. J. Intern. Med. 2013, 273:114-127.
29. Panieri E., Toietta G., Mele M., Labate V., Ranieri S.C., Fusco S., Tesori V., Antonini A., Maulucci G., Spirito M.D., Galeotti T., Pani G. Nutrient withdrawal rescues growth factor-deprived cells from mTOR-dependent damage. Aging (Albany, NY) 2010, 2:487-503.
30. Tabruyn S.P., Griffioen A.W. A new role for NF-[kappa]B in angiogenesis inhibition. Cell Death Differ. 2007, 14:1393-1397.
31. Tong Y.G., Zhang X.W., Geng M.Y., Yue J.M., Xin X.L., Tian F., Shen X., Tong L.J., Li M.H., Zhang C., Li W.H., Lin L.P., Ding J. Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin. Mol. Pharmacol. 2006, 69:1226-1233.
32. Liu M Wang G., Xiao L Xu X., Liu X Xu P., Lin X. Bis(2,3-dibromo-4,5-dihydroxybenzyl) ether, a marine algae derived bromophenol, inhibits the growth of Botrytis cinerea and interacts with DNA molecules. Mar. Drugs 2014, 12:3838-3851.
33. Liang X., Xu F., Li X., Ma C., Zhang Y., Xu W. VEGF signal system: the application of antiangiogenesis. Curr. Med. Chem. 2014, 21:894-910.
34. Murphy A., Makonnen S., Lassoued W., Feldman D., Carter C., Lee W.M.F. Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by Sorafenib (BAY43-9006). Am. J. Pathol. 2006, 169:1875-1885.